{"pmid":32419517,"title":"Emerging therapies for COVID-19 pneumonia.","text":["Emerging therapies for COVID-19 pneumonia.","Expert Opin Investig Drugs","Battaglini, Denise","Robba, Chiara","Ball, Lorenzo","Cruz, Fernanda Ferreira","Silva, Pedro Leme","Pelosi, Paolo","Rocco, Patricia Rieken Macedo","32419517"],"journal":"Expert Opin Investig Drugs","authors":["Battaglini, Denise","Robba, Chiara","Ball, Lorenzo","Cruz, Fernanda Ferreira","Silva, Pedro Leme","Pelosi, Paolo","Rocco, Patricia Rieken Macedo"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32419517","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1080/13543784.2020.1771694","keywords":["covid-19","sars-cov-2","antiretroviral","antithrombotic","clinical trial","coronavirus","mesenchymal stromal cells","pandemic","respiratory failure"],"topics":["Treatment"],"weight":1,"_version_":1667159284467630080,"score":9.490897,"similar":[{"pmid":32472653,"title":"Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome.","text":["Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome.","Severe cases of COVID-19 infection, often leading to death, have been associated with variants of acute respiratory distress syndrome (ARDS). Cell therapy with mesenchymal stromal cells (MSCs) is a potential treatment for COVID-19 ARDS based on preclinical and clinical studies supporting the concept that MSCs modulate the inflammatory and remodeling processes and restore alveolo-capillary barriers. The authors performed a systematic literature review and random-effects meta-analysis to determine the potential value of MSC therapy for treating COVID-19-infected patients with ARDS. Publications in all languages from 1990 to March 31, 2020 were reviewed, yielding 2691 studies, of which nine were included. MSCs were intravenously or intratracheally administered in 200 participants, who were followed for 14 days to 5 years. All MSCs were allogeneic from bone marrow, umbilical cord, menstrual blood, adipose tissue, or unreported sources. Combined mortality showed a favorable trend but did not reach statistical significance. No related serious adverse events were reported and mild adverse events resolved spontaneously. A trend was found of improved radiographic findings, pulmonary function (lung compliance, tidal volumes, PaO2 /FiO2 ratio, alveolo-capillary injury), and inflammatory biomarker levels. No comparisons were made between MSCs of different sources.","Stem Cells Transl Med","Qu, Wenchun","Wang, Zhen","Hare, Joshua M","Bu, Guojun","Mallea, Jorge M","Pascual, Jorge M","Caplan, Arnold I","Kurtzberg, Joanne","Zubair, Abba C","Kubrova, Eva","Engelberg-Cook, Erica","Nayfeh, Tarek","Shah, Vishal P","Hill, James C","Wolf, Michael E","Prokop, Larry J","Murad, M Hassan","Sanfilippo, Fred P","32472653"],"abstract":["Severe cases of COVID-19 infection, often leading to death, have been associated with variants of acute respiratory distress syndrome (ARDS). Cell therapy with mesenchymal stromal cells (MSCs) is a potential treatment for COVID-19 ARDS based on preclinical and clinical studies supporting the concept that MSCs modulate the inflammatory and remodeling processes and restore alveolo-capillary barriers. The authors performed a systematic literature review and random-effects meta-analysis to determine the potential value of MSC therapy for treating COVID-19-infected patients with ARDS. Publications in all languages from 1990 to March 31, 2020 were reviewed, yielding 2691 studies, of which nine were included. MSCs were intravenously or intratracheally administered in 200 participants, who were followed for 14 days to 5 years. All MSCs were allogeneic from bone marrow, umbilical cord, menstrual blood, adipose tissue, or unreported sources. Combined mortality showed a favorable trend but did not reach statistical significance. No related serious adverse events were reported and mild adverse events resolved spontaneously. A trend was found of improved radiographic findings, pulmonary function (lung compliance, tidal volumes, PaO2 /FiO2 ratio, alveolo-capillary injury), and inflammatory biomarker levels. No comparisons were made between MSCs of different sources."],"journal":"Stem Cells Transl Med","authors":["Qu, Wenchun","Wang, Zhen","Hare, Joshua M","Bu, Guojun","Mallea, Jorge M","Pascual, Jorge M","Caplan, Arnold I","Kurtzberg, Joanne","Zubair, Abba C","Kubrova, Eva","Engelberg-Cook, Erica","Nayfeh, Tarek","Shah, Vishal P","Hill, James C","Wolf, Michael E","Prokop, Larry J","Murad, M Hassan","Sanfilippo, Fred P"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32472653","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/sctm.20-0146","keywords":["covid-19","acute respiratory distress syndrome","mesenchymal stromal cells","mortality","systematic review"],"topics":["Treatment"],"weight":1,"_version_":1668255193447268353,"score":64.40958},{"pmid":32424489,"title":"Data Analysis of Infection Rates Among Exposed Healthcare Workers Could Reveal Effective Prophylactics Against SARS-CoV-2.","text":["Data Analysis of Infection Rates Among Exposed Healthcare Workers Could Reveal Effective Prophylactics Against SARS-CoV-2.","The global crisis provoked by the SARS-CoV-2 pandemic, and the economic and social consequences associated to the essential policies applied to contain it, necessitates the expedited development of therapeutic solutions. It is a priority to produce data both rapidly and accurately in order to identify current therapies that can be repurposed to offer protection from SARS-CoV-2 infection. As healthcare workers are both at high risk for infection and able to be readily diagnosed, they offer a potential wealth of data to be analyzed. A systematic data analysis of exposure and infection rates among healthcare workers could yield patterns identifying common protective factors, such as medications with prophylactic potential against SARS-CoV-2, that can be fast-tracked into available therapies. With results suggesting their activity against other coronaviruses and their widespread adoption, Antiretroviral cocktails could be a promising initial target for such large-scale data analysis approach.","Adv Exp Med Biol","Nunez-Mujica, Guido","Kichuk, Therese","Carrasco-Lopez, Cesar","32424489"],"abstract":["The global crisis provoked by the SARS-CoV-2 pandemic, and the economic and social consequences associated to the essential policies applied to contain it, necessitates the expedited development of therapeutic solutions. It is a priority to produce data both rapidly and accurately in order to identify current therapies that can be repurposed to offer protection from SARS-CoV-2 infection. As healthcare workers are both at high risk for infection and able to be readily diagnosed, they offer a potential wealth of data to be analyzed. A systematic data analysis of exposure and infection rates among healthcare workers could yield patterns identifying common protective factors, such as medications with prophylactic potential against SARS-CoV-2, that can be fast-tracked into available therapies. With results suggesting their activity against other coronaviruses and their widespread adoption, Antiretroviral cocktails could be a promising initial target for such large-scale data analysis approach."],"journal":"Adv Exp Med Biol","authors":["Nunez-Mujica, Guido","Kichuk, Therese","Carrasco-Lopez, Cesar"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32424489","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1007/5584_2020_540","keywords":["antiretroviral","antiviral","covid-19","coronavirus","data science","healthcare","vaccine"],"topics":["Treatment","Prevention"],"weight":1,"_version_":1667252837802835969,"score":60.916203},{"pmid":32336723,"title":"Treatment of SARS-CoV-2: How far have we reached?","text":["Treatment of SARS-CoV-2: How far have we reached?","The virus severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is currently affecting more than 200 countries and territories worldwide. It has been declared as pandemic by World Health Organization (WHO) and the whole world is suffering from corona virus disease 2019 (COVID-19). Currently, no treatment for SARS-CoV-2 are approved because of lack of evidence, but a number of clinical trials are in process and we are expecting fruitful results very soon. This review focuses on various approaches of treatment and few of the most recent clinical trials carried out in this field.","Drug Discov Ther","Ahsan, Waquar","Javed, Shamama","Bratty, Mohammed Al","Alhazmi, Hassan A","Najmi, Asim","32336723"],"abstract":["The virus severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is currently affecting more than 200 countries and territories worldwide. It has been declared as pandemic by World Health Organization (WHO) and the whole world is suffering from corona virus disease 2019 (COVID-19). Currently, no treatment for SARS-CoV-2 are approved because of lack of evidence, but a number of clinical trials are in process and we are expecting fruitful results very soon. This review focuses on various approaches of treatment and few of the most recent clinical trials carried out in this field."],"journal":"Drug Discov Ther","authors":["Ahsan, Waquar","Javed, Shamama","Bratty, Mohammed Al","Alhazmi, Hassan A","Najmi, Asim"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32336723","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.5582/ddt.2020.03008","keywords":["sars-cov-2","antiviral","clinical trial","corona virus","pandemic"],"topics":["Treatment"],"weight":1,"_version_":1666138494162960386,"score":56.780212},{"pmid":32441773,"title":"COVID-19 in a patient with HIV infection.","text":["COVID-19 in a patient with HIV infection.","The worldwide pandemic of the novel coronavirus disease 2019 (COVID-19) has raised many challenges and uncertainties regarding disease management and prognosis in immunocompromised patient populations. The concurrence of human immunodeficiency virus (HIV) infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, presents an intriguing problem and only a handful of these cases exist in the literature, despite 37.9 million people living with HIV throughout the world. Previous reports suggest the possibility of a protective factor from standard antiretroviral treatment for HIV patients that could have significant clinical benefits for these patients when co-infected with SARS-CoV-2. HIV patients also generally present with atypical clinical presentation and have a less severe form of COVID-19 than the general population. Here, we present the first case of an HIV positive patient who was diagnosed with COVID-19 in the United States. This article is protected by copyright. All rights reserved.","J Med Virol","Patel, Raj H","Pella, Pablo M","32441773"],"abstract":["The worldwide pandemic of the novel coronavirus disease 2019 (COVID-19) has raised many challenges and uncertainties regarding disease management and prognosis in immunocompromised patient populations. The concurrence of human immunodeficiency virus (HIV) infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, presents an intriguing problem and only a handful of these cases exist in the literature, despite 37.9 million people living with HIV throughout the world. Previous reports suggest the possibility of a protective factor from standard antiretroviral treatment for HIV patients that could have significant clinical benefits for these patients when co-infected with SARS-CoV-2. HIV patients also generally present with atypical clinical presentation and have a less severe form of COVID-19 than the general population. Here, we present the first case of an HIV positive patient who was diagnosed with COVID-19 in the United States. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Patel, Raj H","Pella, Pablo M"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32441773","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/jmv.26049","keywords":["covid-19","hiv","sars-cov-2","antiretroviral","co-infection"],"locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Case Report"],"weight":1,"_version_":1667535119509880833,"score":53.672478},{"pmid":32412125,"title":"Androgen sensitivity gateway to COVID-19 disease severity.","text":["Androgen sensitivity gateway to COVID-19 disease severity.","In this communication, we present arguments for androgen sensitivity as a likely determinant of COVID-19 disease severity. The androgen sensitivity model explains why males are more likely to develop severe symptoms while children are ostensibly resistant to infection. Further, the model explains the difference in COVID-19 mortality rates among different ethnicities. Androgen sensitivity is determined by genetic variants of the androgen receptor. The androgen receptor regulates transcription of the transmembrane protease, serine 2 (TMPRSS2), which is required for SARS-CoV-2 infectivity. TMPRSS2 primes the Spike protein of the virus, which has two consequences: diminishing viral recognition by neutralizing antibodies and activating SARS-CoV-2 for virus-cell fusion. Genetic variants that have been associated with androgenetic alopecia, prostate cancer, benign prostatic hyperplasia and polycystic ovary syndrome could be associated with host susceptibility. In addition to theoretical epidemiological and molecular mechanisms, there are reports of high rates of androgenetic alopecia of from hospitalized COVID-19 patients due to severe symptoms. Androgen sensitivity is a likely determinant of COVID-19 disease severity. We believe that the evidence presented in this communication warrants the initiation of trials using anti-androgen agents.","Drug Dev Res","Wambier, Carlos Gustavo","Goren, Andy","Vano-Galvan, Sergio","Ramos, Paulo Muller","Ossimetha, Angelina","Nau, Gerard","Herrera, Sabina","McCoy, John","32412125"],"abstract":["In this communication, we present arguments for androgen sensitivity as a likely determinant of COVID-19 disease severity. The androgen sensitivity model explains why males are more likely to develop severe symptoms while children are ostensibly resistant to infection. Further, the model explains the difference in COVID-19 mortality rates among different ethnicities. Androgen sensitivity is determined by genetic variants of the androgen receptor. The androgen receptor regulates transcription of the transmembrane protease, serine 2 (TMPRSS2), which is required for SARS-CoV-2 infectivity. TMPRSS2 primes the Spike protein of the virus, which has two consequences: diminishing viral recognition by neutralizing antibodies and activating SARS-CoV-2 for virus-cell fusion. Genetic variants that have been associated with androgenetic alopecia, prostate cancer, benign prostatic hyperplasia and polycystic ovary syndrome could be associated with host susceptibility. In addition to theoretical epidemiological and molecular mechanisms, there are reports of high rates of androgenetic alopecia of from hospitalized COVID-19 patients due to severe symptoms. Androgen sensitivity is a likely determinant of COVID-19 disease severity. We believe that the evidence presented in this communication warrants the initiation of trials using anti-androgen agents."],"journal":"Drug Dev Res","authors":["Wambier, Carlos Gustavo","Goren, Andy","Vano-Galvan, Sergio","Ramos, Paulo Muller","Ossimetha, Angelina","Nau, Gerard","Herrera, Sabina","McCoy, John"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32412125","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1002/ddr.21688","keywords":["covid-19","sars-cov-2","tmprss2","alopecia","androgens","anti-androgen","clinical trial","pandemic"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666989866102030336,"score":51.923534}]}